Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Niagen Bioscience (NAGE) Cash from Investing Activities: 2011-2024

Historic Cash from Investing Activities for Niagen Bioscience (NAGE) over the last 12 years, with Dec 2024 value amounting to -$143,000.

  • Niagen Bioscience's Cash from Investing Activities fell 14.29% to -$24,000 in Q3 2025 from the same period last year, while for Sep 2025 it was -$260,000, marking a year-over-year decrease of 173.68%. This contributed to the annual value of -$143,000 for FY2024, which is negligibly% changed negligibly from last year.
  • Per Niagen Bioscience's latest filing, its Cash from Investing Activities stood at -$143,000 for FY2024, which was down 0.00% from -$143,000 recorded in FY2023.
  • Niagen Bioscience's 5-year Cash from Investing Activities high stood at -$143,000 for FY2023, and its period low was -$409,000 during FY2021.
  • For the 3-year period, Niagen Bioscience's Cash from Investing Activities averaged around -$206,667, with its median value being -$143,000 (2024).
  • Its Cash from Investing Activities has fluctuated over the past 5 years, first tumbled by 147.88% in 2021, then skyrocketed by 57.19% in 2023.
  • Over the past 5 years, Niagen Bioscience's Cash from Investing Activities (Yearly) stood at -$165,000 in 2020, then slumped by 147.88% to -$409,000 in 2021, then increased by 18.34% to -$334,000 in 2022, then spiked by 57.19% to -$143,000 in 2023, then remained steady at -$143,000 in 2024.